Filed under: Uncategorized | Tagged: 5-ht6, 5ht6, phase I, suven | Leave a comment »
Suven begin Phase I trials of 5-HT6 antagonist SUVN-502
Posted on September 25, 2008 by crimsoncanary
GSK publish series of Tricyclic Azepine derivative 5HT6 antagonists
Posted on August 14, 2008 by crimsoncanary
Filed under: gpcr | Tagged: 5-ht6, 5ht6, GSK | Leave a comment »
Suvens 5-HT6 antagonist effective in Alzheimer models
Posted on August 5, 2008 by crimsoncanary
Memory Pharmaceuticals report positive preclinical data for 5-HT6 antagonist
Posted on August 4, 2008 by crimsoncanary
Lillys long acting injection olanzapine shows similar profile to Zyprexa
Posted on June 23, 2008 by crimsoncanary
Filed under: gpcr | Tagged: 5-HT2A, 5-ht2c, 5-HT3, 5-ht6, 5HT2A, 5Ht2c, 5HT3, 5ht6, antagonist, D1, D2, D4, Dopamine, Lilly, M1, Muscarinic, Muscarinic M1, olanzapine, Zyprexa | Leave a comment »
MEM 68626 selected as lead 5-HT6 Antagonist for the treatment of cognitive disorders and obesity
Posted on May 16, 2008 by crimsoncanary